

14 August 2015

Announcements

National Stock Exchange of Australia

PO Box 283

NEWCASTLE NSW 2300

Market Announcement – Update on Nasdaq cross-listing

Further to its announcement on 3 March 2015 whereby iQX Limited (NSX:IQX) (the Company) announced its intention to commence the process to list the Company's depository receipts on the Nasdaq Capital Markets USA, the company would like to further announce that it has reserved the Nasdaq ticker symbol "IQX" for the period until 17 February 2017. The company is now in the planning and preparatory phase with its US legal and corporate advisors to address the listing criteria of the Nasdaq Capital Markets USA.

The Company will provide further updates on the listing process in due course.



Kelvin Boateng

Company Secretary

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQX's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQX Limited

IQX Ltd is a specialist life science investment and fund management organisation,

Sydney: 222 Clarence Street, Sydney, NSW 2000, Australia *Phone: +61 2 8239 5400 *Fax: +61 2 8362 9325

New York: 200 Park Avenue, Suite 1700, New York City, NY, USA 10166 •

London: 5 Harbour Exchange, Harbour Exchange Square, Canary Wharf E14 9GE UK•